Dexamethasone-21-acetate | 987-24-6

• 物质功能分类: 原料药 - 激素及调节内分泌功能类药 - 肾上腺皮质激素类药
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Dexamethasone-21-acetate
• 英文别名: [2-(9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl)-2-oxoethyl] acetate
• CAS: 987-24-6
• 化学式: C₂₄H₃₁FO₆
• 分子量: 434.5
• InChiKey: AKUJBENLRBOFTD-UHFFFAOYSA-N

物化性质

• 熔点：
  200-220°C (dec.)
• 比旋光度：
  D +140° (chloroform)
• 沸点：
  579.4±50.0 °C(Predicted)
• 密度：
  1.0932 (rough estimate)
• 溶解度：
  几乎不溶于水，易溶于丙酮，溶于乙醇（96%）和二氯甲烷。它显示多态性(5.9)。

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  7

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S22,S36
• 危险类别码：
  R40
• WGK Germany：
  3
• 海关编码：
  2937220000
• 储存条件：
  Refrigerator

SDS

---

Section 1. Chemical Product and Company Identification
Betamethasone acetate Catalog
YY1144, BE182
Common Name/
Number(s).
Trade Name
CAS# 987-24-6
Manufacturer
RTECS Not available.
SPECTRUM QUALITY PRODUCTS INC.
TSCA TSCA 8(b) inventory: No
products were found.
Commercial Name(s) Not available.
CI# Not available.
Synonym 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
IN CASE OF EMERGENCY
acetate
Chemical Name Not available.
Not available. CALL [phone]
Chemical Family
Chemical Formula C24H31FO6
SPECTRUM QUALITY PRODUCTS INC.

---

Section 2.Composition and Information on Ingredients
Exposure Limits
TWA (mg/m3) STEL (mg/m3) CEIL (mg/m3)
Name CAS # % by Weight
1) Betamethasone acetate 987-24-6 100
Toxicological Data Not applicable.
on Ingredients

---

Section 3. Hazards Identification
Potential Acute Health Effects Hazardous in case of ingestion. Slightly hazardous in case of skin contact (irritant), of eye contact (irritant), of
inhalation.
Potential Chronic Health Hazardous in case of ingestion.
Effects Slightly hazardous in case of skin contact (irritant), of eye contact (irritant), of inhalation.
CARCINOGENIC EFFECTS: Not available.
MUTAGENIC EFFECTS: Not available.
TERATOGENIC EFFECTS: Not available.
DEVELOPMENTAL TOXICITY: Not available.
Betamethasone acetate

---

Section 4. First Aid Measures
Eye Contact Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at
least 15 minutes. Get medical attention if irritation occurs.
Skin Contact Wash with soap and water. Cover the irritated skin with an emollient. Get medical attention if irritation develops.
Serious Skin Contact Not available.
Inhalation If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get
medical attention.
Serious Inhalation Not available.
Ingestion Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an
unconscious person. If large quantities of this material are swallowed, call a physician immediately. Loosen tight
clothing such as a collar, tie, belt or waistband.
Serious Ingestion Not available.

---

Section 5. Fire and Explosion Data
Flammability of the Product May be combustible at high temperature.
Auto-Ignition Temperature Not available.
Flash Points Not available.
Flammable Limits Not available.
Products of Combustion These products are carbon oxides (CO, CO2), halogenated compounds.
Fire Hazards in Presence of Not available.
Various Substances
Explosion Hazards in Presence Risks of explosion of the product in presence of mechanical impact: Not available.
Risks of explosion of the product in presence of static discharge: Not available.
of Various Substances
SMALL FIRE: Use DRY chemical powder.
Fire Fighting Media
and Instructions LARGE FIRE: Use water spray, fog or foam. Do not use water jet.
Not available.
Special Remarks on
Fire Hazards
Special Remarks on Explosion Not available.
Hazards

---

Section 6. Accidental Release Measures
Small Spill Use appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by
spreading water on the contaminated surface and dispose of according to local and regional authority
requirements.
Large Spill Use a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading water
on the contaminated surface and allow to evacuate through the sanitary system.
Betamethasone acetate

---

Section 7. Handling and Storage
Precautions Keep away from heat. Keep away from sources of ignition. Empty containers pose a fire risk, evaporate the
residue under a fume hood. Ground all equipment containing material. Do not breathe dust.
Storage Keep container tightly closed. Keep container in a cool, well-ventilated area.

---

Section 8. Exposure Controls/Personal Protection
Engineering Controls Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below
recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to
airborne contaminants below the exposure limit.
Personal Protection
Safety glasses. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Gloves.
Personal Protection in Case of Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be used
a Large Spill to avoid inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist
BEFORE handling this product.
Exposure Limits Not available.

---

Section 9. Physical and Chemical Properties
Physical state and appearance Solid. (Powdered solid.) Odor Not available.
Taste Not available.
Molecular Weight 434.5 g/mole
Color Not available.
pH (1% soln/water) Not applicable.
Boiling Point Decomposes.
Melting Point 206.5°C (403.7°F)
Critical Temperature Not available.
Not available.
Specific Gravity
Vapor Pressure Not applicable.
Vapor Density Not available.
Volatility Not available.
Odor Threshold Not available.
Not available.
Water/Oil Dist. Coeff.
Ionicity (in Water) Not available.
See solubility in water, methanol.
Dispersion Properties
Solubility Partially soluble in methanol.
Insoluble in cold water.

---

Section 10. Stability and Reactivity Data
Stability The product is stable.
Instability Temperature Not available.
Conditions of Instability Not available.
Incompatibility with various Not available.
substances
Corrosivity Non-corrosive in presence of glass.
Betamethasone acetate
Not available.
Special Remarks on
Reactivity
Not available.
Special Remarks on
Corrosivity
Polymerization Will not occur.

---

Section 11. Toxicological Information
Routes of Entry Ingestion.
Toxicity to Animals LD50: Not available.
LC50: Not available.
Chronic Effects on Humans Not available.
Other Toxic Effects on
Hazardous in case of ingestion.
Humans Slightly hazardous in case of skin contact (irritant), of inhalation.
Special Remarks on
Not available.
Toxicity to Animals
Special Remarks on Not available.
Chronic Effects on Humans
Special Remarks on other Not available.
Toxic Effects on Humans

---

Section 12. Ecological Information
Ecotoxicity Not available.
Not available.
BOD5 and COD
Possibly hazardous short term degradation products are not likely. However, long term degradation products may
Products of Biodegradation
arise.
Toxicity of the Products The products of degradation are more toxic.
of Biodegradation
Special Remarks on the Not available.
Products of Biodegradation

---

Section 13. Disposal Considerations
Waste Disposal

---

Section 14. Transport Information
DOT Classification Not a DOT controlled material (United States).
Identification Not applicable.
Not applicable.
Special Provisions for
Transport
DOT (Pictograms)
Betamethasone acetate

---

Section 15. Other Regulatory Information and Pictograms
TSCA 8(b) inventory: No products were found.
Federal and State
Regulations
California
Proposition 65
Warnings
Other Regulations Not available.
WHMIS (Canada) Not controlled under WHMIS (Canada).
Other Classifications
DSCL (EEC) This product is not classified according
to the EU regulations.
Health Hazard
HMIS (U.S.A.) 1 National Fire Protection
1 Flammability
1 Association (U.S.A.)
Fire Hazard
1 0 Reactivity
Health
Reactivity
0
Specific hazard
Personal Protection
E
WHMIS (Canada)
(Pictograms)
DSCL (Europe)
(Pictograms)
TDG (Canada)
(Pictograms)
ADR (Europe)
(Pictograms)
Protective Equipment
Gloves.
Lab coat.
Dust respirator. Be sure to use an
approved/certified respirator or
equivalent.
Safety glasses.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

醋酸倍他米松简介

醋酸倍他米松是一种固醇类药物，广泛用于治疗多种风湿免疫性疾病，包括类风湿性关节炎、全身性红斑狼疮以及皮肤炎和银屑病等免疫性皮肤疾病。此外，它还适用于哮喘及血管水肿等过敏性疾病，并能在早产时协助胎儿肺部发育。

功效

醋酸倍他米松属于类固醇药物，其主要功效为消炎作用。这种药物常用于局部炎症的短期治疗。

适应症

醋酸倍他米松是一种固醇类药物，适用于多种风湿免疫性疾病，如类风湿性关节炎、全身性红斑狼疮及皮肤炎和银屑病等免疫性皮肤疾病。此外，它还适用于哮喘及血管水肿等过敏性疾病，并可在早产时帮助胎儿肺部发育。

副作用

醋酸倍他米松的严重副作用包括增加感染风险、肌肉无力、全身型过敏反应以及思觉失调。长期使用可能会导致肾上腺机能不足，因此突然停药非常危险。对于常使用含有倍他米松成分软膏的人群来说，可能还会出现多毛症及皮肤敏感的情况。

反应信息

• 作为反应物：
  描述：

  Dexamethasone-21-acetate 生成 betamethasone
  参考文献：
  名称：

  一种地塞米松磷酸钠的制备方法

  摘要：

  本发明涉及一种地塞米松磷酸钠的制备方法，包括以下步骤：开环反应：以醋酸地塞米松环氧物为起始原料，加入HF、DMF，反应3h进行开环反应得到醋酸地塞米松溶液；重结晶：向醋酸地塞米松溶液中加入甲醇进行重结晶得到醋酸地塞米松；碱催化水解：醋酸地塞米松加入到Na2CO3和甲醇中，反应10min后得到地塞米松；焦磷酰氯酯化：将步骤3）得到的地塞米松与焦磷酰氯、THF反应得到地塞米松磷酸酯；中和成盐反应：将步骤4）得到的地塞米松磷酸酯与NaOH、甲醇反应，反应温度20℃～30℃，反应时间1h得到地塞米松磷酸钠。本发明制备地塞米松磷酸钠的步骤简单，原料易得，反应条件温和，适合于工业化生产，且成本低廉。

  公开号：

  CN105348358A
• 作为产物：
  描述：

  21-O-乙酰基地塞米松9,11-环氧化物 生成 Dexamethasone-21-acetate
  参考文献：
  名称：

  一种地塞米松磷酸钠的制备方法

  摘要：

  本发明涉及一种地塞米松磷酸钠的制备方法，包括以下步骤：开环反应：以醋酸地塞米松环氧物为起始原料，加入HF、DMF，反应3h进行开环反应得到醋酸地塞米松溶液；重结晶：向醋酸地塞米松溶液中加入甲醇进行重结晶得到醋酸地塞米松；碱催化水解：醋酸地塞米松加入到Na2CO3和甲醇中，反应10min后得到地塞米松；焦磷酰氯酯化：将步骤3）得到的地塞米松与焦磷酰氯、THF反应得到地塞米松磷酸酯；中和成盐反应：将步骤4）得到的地塞米松磷酸酯与NaOH、甲醇反应，反应温度20℃～30℃，反应时间1h得到地塞米松磷酸钠。本发明制备地塞米松磷酸钠的步骤简单，原料易得，反应条件温和，适合于工业化生产，且成本低廉。

  公开号：

  CN105348358A

文献信息

• Agents, Uses and Methods
  申请人：Graversen Niels Jonas Heilskov

  公开号：US20120258107A1

  公开（公告）日：2012-10-11

  The present invention relates to agents comprising a binding moiety with binding specificity for SRCR domain 1 of the CD163 receptor, for use in medicine. The invention also relates to methods, uses, kits and compositions comprising such agents.

  本发明涉及一种代理物，其包括具有结合特异性的结合基团，用于与CD163受体的SRCR域1结合，在医学中使用。本发明还涉及包括这种代理物的方法、用途、试剂盒和组合物。
• Autoclavable pharmaceutical compositions containing a chelating agent
  申请人：Novartis AG

  公开号：EP0938896A1

  公开（公告）日：1999-09-01

  The present invention describes an autoclavable ophthalmic composition comprising an ophthalmically effective drug. The invention further relates to a process for the manufacture of such a composition and to the use of said compositions.

  本发明描述了一种包含眼科有效药物的可高压灭菌眼科组合物。本发明还涉及制造这种组合物的工艺和所述组合物的用途。
• Pharmaceutical compositions comprising ketotifen
  申请人：Novartis AG

  公开号：EP1172098A1

  公开（公告）日：2002-01-16

  The present invention describes an autoclavable ophthalmic composition comprising an ophthalmically effective drug. The invention further relates to a method for stabilizing an ophthalmic drug.

  本发明描述了一种包含眼科有效药物的可高压灭菌眼科组合物。本发明还涉及一种稳定眼科药物的方法。
• NOVEL HETEROCYCLIC COMPOUND AND ANTI-INFLAMMATORY AGENT
  申请人：NIPPON SODA CO., LTD.

  公开号：EP1435353A1

  公开（公告）日：2004-07-07

  A compound represented by the formula [I]: [I] (wherein X represents oxygen, sulfur, NR4, or CHR5; Y represents oxygen or sulfur; R1 represents C1-6 alkyl, etc.; R2 represents optionally substituted phenyl, etc.; and R3 represents optionally substituted C1-6 alkyl, a group represented by any of the following formulae, etc.) [II] or a pharmaceutically acceptable composite of the compound; a medicinal composition containing any of these as an active ingredient; and a use thereof, etc.

  由式[I]代表的化合物：[I]（其中 X 代表氧、硫、NR4 或 CHR5；Y 代表氧或硫；R1 代表 C1-6 烷基等；R2 代表任选取代的苯基等；R3 代表任选取代的 C1-6 烷基、下式中任一式所代表的基团等）[II]或该化合物的药学上可接受的复合物；含有上述任一式作为活性成分的药物组合物；及其用途等。
• Eye drop composition comprising ketotifen
  申请人：Novartis AG

  公开号：EP2281554A1

  公开（公告）日：2011-02-09

  The present invention describes an autoclavable ophthalmic composition comprising ketotifen.

  本发明描述了一种含有酮替芬的可高压灭菌眼科组合物。